Maze Therapeutics, Inc. (MAZE) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-25

How it makes money

It has generated zero product revenue since inception, relying instead on equity sales, debt, and one-time licensing payments.

As a clinical-stage biopharmaceutical company, it does not sell commercial products and has no product revenue today. Operations are instead financed through equity sales, convertible notes, debt financing, and upfront licensing payments from corporate partners.

Future earnings depend entirely on successfully advancing its small molecule pipeline—such as lead programs MZE829 for kidney disease and MZE782 for metabolic disorders—through clinical trials, gaining regulatory approvals, and ultimately commercializing treatments or securing additional lucrative partnership agreements.

What protects it: the moat

Management asserts that its proprietary Compass platform and intellectual property portfolio protect its drug discovery and development process.

It relies on its Compass platform to identify genetic variants, characterize disease risks, and inform clinical trial design for precision medicines targeting kidney and metabolic conditions. Management intends to expand its intellectual property portfolio through patent filings and potential in-licensing opportunities to safeguard its therapeutic candidates from competitors.

However, because the company is still in clinical stages without approved commercial products, these technological and patent advantages remain unproven in the marketplace. Competitors pursuing similar genetic insights or small molecule inhibitors could develop alternative therapies.

What growth costs

It burns significant capital on research, clinical trials, and personnel as it advances its unapproved pipeline candidates.

Operating expenses are driven by heavy investments in research and development, preclinical studies, and ongoing clinical trials for lead candidates MZE829 and MZE782. For the years ended December 31, 2025 and 2024, it incurred a net loss of $131.1 million and net income of $52.2 million, respectively, bringing its accumulated deficit to $489.5 million as of December 31, 2025.

To maintain and grow its operations, it must continue funding expensive clinical programs, expand its intellectual property portfolio, hire specialized personnel, and cover public company costs. Management expects operating losses to increase significantly for the foreseeable future as these development efforts scale up.

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Other companies in Biotechnology